acebrophylline + montelukast + fexofenadine

Acebrol FM is a fixed-dose combination tablet containing acebrophylline, montelukast, and fexofenadine, developed by Wellcure Pharmacorp. It is indicated for the treatment of chronic obstructive respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), particularly when complicated by allergic rhinitis. Acebrophylline acts as a bronchodilator and mucolytic agent by inhibiting phospholipase A2 and phosphodiesterase, which helps in reducing airway inflammation and improving mucus clearance. Montelukast is a selective leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes, thereby reducing bronchoconstriction and inflammation. Fexofenadine is a second-generation H1-antihistamine that provides relief from allergic symptoms without causing significant sedation. Together, these components offer a comprehensive therapeutic approach to managing both the obstructive and allergic components of respiratory disease.

Brand names

Acebrol FM

Other names

Acebrol FM TAB